Hero

Celyad to Present Updates on CYAD-01 at the American Association for Cancer Research (AACR) Annual Meeting 2018

1

Celyad to Present Updates on CYAD-01 at the American Association for Cancer Research (AACR) Annual Meeting 2018

Celyad Reports 2017 Financial and Operating Results and Expected Key Milestones for 2018

2

Celyad Reports 2017 Financial and Operating Results and Expected Key Milestones for 2018

Celyad Provides Clinical Update and Strategic Outlook for 2018

3

Celyad Provides Clinical Update and Strategic Outlook for 2018

About Celyad

Making the Impossible Possible

Celyad is a clinical-stage biopharmaceutical that is developing next generation CAR-T NK cell-based immunotherapies for cancer treatment.

Latest News

Celyad to Present Updates on CYAD-01 at the American Association for Cancer Research (AACR) Annual Meeting 2018

Celyad to Present Updates on CYAD-01 at the American Association for Cancer Research (AACR) Annual Meeting 2018

Celyad Reports 2017 Financial and Operating Results and Expected Key Milestones for 2018

Celyad Reports 2017 Financial and Operating Results and Expected Key Milestones for 2018

Celyad to Host Key Opinion Leader Meeting on CAR-T Therapy for the Treatment of Blood Cancers

Celyad to Host Key Opinion Leader Meeting on CAR-T Therapy for the Treatment of Blood Cancers

Discover all news

Carousel

Social Feed

@CelyadSA is proud to support AML patients, on #AML Awareness day and every day. #KnowAML https://t.co/iHiZxeBT2N

1 day ago

@CelyadSA is proud to support AML patients, on #AML Awareness day and every day. #KnowAML https://t.co/iHiZxeBT2N

Today is the AML World Awareness day! Joins us to support AML patients! https://t.co/SefIVoHBZq

1 day ago

Today is the AML World Awareness day! Joins us to support AML patients! https://t.co/SefIVoHBZq

One more day until #AMLawarenessday! Support @KNOW_AML the world’s first global AML awareness initiative, that aims… https://t.co/M4hS4zZrCg

2 days ago

One more day until #AMLawarenessday! Support @KNOW_AML the world’s first global AML awareness initiative, that aims… https://t.co/M4hS4zZrCg

Interview of @ChristianHomsy, CEO @CelyadSA : “This is the First Time CAR-T Has Ever Worked on Acute Myeloid Leukem… https://t.co/RTHINhYy8p

3 days ago

Interview of @ChristianHomsy, CEO @CelyadSA : “This is the First Time CAR-T Has Ever Worked on Acute Myeloid Leukem… https://t.co/RTHINhYy8p

@CelyadSA is proud to support AML patients, on #AML Awareness day and every day. #KnowAML https://t.co/iHiZxeBT2N

1 day ago

@CelyadSA is proud to support AML patients, on #AML Awareness day and every day. #KnowAML https://t.co/iHiZxeBT2N

Today is the AML World Awareness day! Joins us to support AML patients! https://t.co/SefIVoHBZq

1 day ago

Today is the AML World Awareness day! Joins us to support AML patients! https://t.co/SefIVoHBZq

One more day until #AMLawarenessday! Support @KNOW_AML the world’s first global AML awareness initiative, that aims… https://t.co/M4hS4zZrCg

2 days ago

One more day until #AMLawarenessday! Support @KNOW_AML the world’s first global AML awareness initiative, that aims… https://t.co/M4hS4zZrCg

Interview of @ChristianHomsy, CEO @CelyadSA : “This is the First Time CAR-T Has Ever Worked on Acute Myeloid Leukem… https://t.co/RTHINhYy8p

3 days ago

Interview of @ChristianHomsy, CEO @CelyadSA : “This is the First Time CAR-T Has Ever Worked on Acute Myeloid Leukem… https://t.co/RTHINhYy8p